A deeper understanding of these pathways could lead to the development of novel therapies: a monoclonal antibody targeting PTHrP represents a promising therapeutic strategy in combating breast cancer, particularly in aggressive forms like triple‐negative breast cancer (TNBC) in which PTHrP has shown a role in brain metastases development, but no effect on skeletal involvement was mentioned [88]. The gene discussed is PTHLH; the disease is breast cancer.